What is tulisokibart?

It is an anti-TL1A antibody being developed for ulcerative colitis, showing positive Phase 3 results.

What new FDA approvals did Merck receive?

Expanded approvals for KEYTRUDA and WELIREG in kidney cancer, and expanded indication for CAPVAXIVE vaccine for high-risk children and adolescents.

How do these updates affect Merck's investment story?

They show Merck's strategy to diversify beyond oncology, potentially reducing reliance on KEYTRUDA and opening new revenue streams.

Merck Achieves Immunology and Vaccine Milestones, Broadens Portfolio

In June 2026, Merck (MRK) announced positive Phase 3 results for its anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis, along with FDA approvals expanding KEYTRUDA-WELIREG in kidney cancer and CAPVAXIVE for high-risk children and adolescents, strengthening its portfolio beyond oncology.

Merck (MRK) reported in June 2026 positive Phase 3 results for tulisokibart, an anti-TL1A antibody, in patients with moderately to severely active ulcerative colitis. Additionally, the U.S. FDA approved expanded uses for KEYTRUDA and WELIREG in kidney cancer and broadened the indication for CAPVAXIVE vaccine to include high-risk children and adolescents. These updates highlight Merck's push to diversify beyond oncology.

Tulisokibart for Ulcerative Colitis

Tulisokibart showed positive Phase 3 results for moderately to severely active ulcerative colitis. Detailed data have not yet been disclosed, but the outcome is a key step in building Merck's immunology pipeline.

Expanded KEYTRUDA and WELIREG Approvals

The FDA approved expanded use of KEYTRUDA (pembrolizumab) and WELIREG (belzutifan) for renal cell carcinoma. KEYTRUDA is Merck's top-selling drug, and this expansion aims to maintain its market position.

CAPVAXIVE Indication Expansion

CAPVAXIVE (pneumococcal vaccine) received FDA approval for use in children and adolescents aged 6 weeks to 17 years at increased risk. This is expected to boost vaccine revenue.

Impact on Merck

These updates reflect Merck's strategy to diversify revenue streams and reduce reliance on KEYTRUDA, which faces growing competition. Progress in immunology and vaccines offers new growth avenues.

What This Means for Investors

Investors should monitor detailed tulisokibart data and quarterly sales to assess financial impact. Expanded indications may boost long-term revenue, but market competition remains intense.